Seres Aims To File C. Diff Microbiome Drug On Single Pivotal Trial

 
• By Joseph Haas

Competing with several other firms to bring the first microbiome-derived therapy to market, Seres says the magnitude of its Phase III efficacy compared to placebo may enough for registrational filing.

Clostridium difficile bacteria, 3D illustration. Spore-forming bacteria that cause pseudomembraneous colitis and are associated with nosocomial antibiotic resistance
Seres hopes to improve the standard of care in recurrent C. diff with a microbiome therapy

More from Clinical Trials

More from R&D